Abstract
Quinacrine sterilization (QS) involves transcervical insertion of quinacrine pellets using a modified Copper T IUD inserter. Pellets are placed at the fundus in the proliferative phase of the menstrual cycle. Efficacy is presently estimated at 1 pregnancy failure per 100 women at 2 years. Early complications are lower for QS than surgical sterilization and this is also true for risk of ectopic pregnancy with newer insertion protocols. The risk of birth defects is very low, when estimated from a model with reasonable assumptions for probability of insertion in a pregnant uterus or within 30 days of conception, probability of such exposed pregnancy being carried to term, and probability of quinacrine exposure to the fetus causing a birth defect. Although quinacrine is a mutagen it is unlikely to be a carcinogen. Concentrations of quinacrine in the uterus after transcervical insertion are higher than for oral administration for only a matter of a few hours, although this brief exposure is adequate to cause injury to the tubal epithelium, leading to inflammation and an occluding scar. Oral administration of quinacrine is accepted as non-carcinogenic. Each site of use of QS must make its own risk/benefit assessment. The benefits of any contraceptive that can raise contraceptive prevalence is greatest for developing countries.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Sadik N. The State of World Population 1997. United Nations Population Fund, New York, 1997.
State Family Planning Commission. Population and Family Planning in China. Beijing, 1997.
Central Bureau of Statistics (CBS) [Indonesia] and State Ministry of Population/National Family Planning Coordinating Board (NFPCB) and Ministry of Health (MOH) and Macro International Inc. (MI). 1995. Indonesia Demographic and Health Survey 1994. Calverton, Maryland: CBS and MI, p. 76, Table 5.2.2.
General Statistical Office. 1994 Inter-Censal Demographic Survey. Statistical Publishing House, Hanoi, May 1995.
National Population Council (NPC) and Macro International Inc. (MI). Egypt Demographic and Health Survey 1996. Calverton, Maryland: NPC and MI; 1997.
Klitsch M. Sterilization without surgery. Int Fam Plann Perspect 1982;8:101–4. 88 Kessel
Zipper J, Cole LP, Goldsmith A, Wheeler R, Rivera M. Quinacrine hydrochloride pellets: preliminary data on a nonsurgical method of female sterilization. Int J Gynaecol Obstet. 1980;18:265–9.
Kessel E. 100,000 quinacrine sterilizations. Adv Contracept. 1996;12:69–76.
Peterson HB, Xia Z, Hughes JM, Wilcox LS, Taylor LR, Trussell V. The risk of ectopic pregnancy after tubal sterilization. N Engl J Med. 1997;336:762–7.
Hieu DT, Tan TT, Tan DN, Nguyet PT, Than P, Vinh DQ. 31 781 cases of non-surgical female sterilisation with quinacrine pellets in Vietnam. Lancet. 1993;342:213–7.
Franks AL, Beral V, Cates W, Hogue CJR. Contraception and ectopic pregnancy risk. Am J Obstet Gynecol. 1990;163:1120–3.
Sokal DC, Zipper J, King T. Transcervical quinacrine sterilization: clinical experience. Int J Gynecol Obstet. 1995;51(suppl):556–69.
Peterson HB, Zhisen X, Hughes J, et al. The risk of pregnancy after tubal sterilization: finding from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol. 1996;174:1161–70.
Soroodi-Maghaddam S. Preliminary report on a clinical trial of the quinacrine pellet method for nonsurgical female sterilization in Iran. Int Fam Plann Perspect. 1996; 22:122–3, 127.
Bairagi NR, Mullick BC, Kessel E, Mumford SD. Comparison of the efficacy of intrauterine diclofenac and ibuprofen pellets as adjuvants to quinacrine nonsurgical female sterilization. Adv Contracept. 1995;11:303–8.
Institute for Development Training. Female voluntary non-surgical sterilization: The quinacrine method. Module 12 of Training Course in Women's Health. Institute for Development Training, Chapel Hill, 1996.
Rock JA, Parmley TH, King TM, Laufe LE, Su BC. Endometriosis and the development of tuboperitoneal fistulas after tubal ligation. Fertil Steril. 1981;35:16–20.
Blake DA, Dubin NH, Blasé MC, Parmley TM, Stetten G, King TM. Teratologic and mutagenic studies with intrauterine quinacrine hydrochloride. In: Zatuchni GI, Shelton JD, Goldsmith A, Sciarra JJ, eds. Female Transcervical Sterilization. Philadelphia, Harper and Row, 1983, p. 71–88.
Bartsch H, Malaveille C. Prevalence of genotoxic chemicals among animal and human carcinogens evaluated in the IARC Monograph Series. Cell Biol Toxicol. 1989;5(2):115–27.
Wiltse J, Dellarco VL. U.S. Environmental Protection Agency Guidelines for carcinogenic risk assessment: Past and future. Mutation Res. 1996;365:3–15.
Cohen SM, Ellwein LB. Cell proliferation in carcinogenesis. Science. 1990;249:1007–11.
Tice RR, Griffith J, Recio L. An evaluation of the mutagenicity and carcinogenicity of quinacrine. Family Health International 1990. Research Triangle Park, NC. pp. 27.
Fitzhugh OG, Nelson AA, Calvery HO. The chronic toxicity of quinacrine (atabrine). J Pharmacol Exp Ther. 1945;85:207–21.
Dabancens A, Zipper J, Guerrero A. Quinacrine and copper, compounds with anticonceptive and antineoplastic activity. Contraception. 1994;50:243–51.
Sokal DC, Zipper J, Guzman-Serani R, Aldrich TE. Cancer risk among women sterilized with transcervical quinacrine hydrochloride pellets, 1988-1991. Fertil Steril. 1995;64:324–34.
Cahn RS, Dermer OC. Introduction to Chemical Nomenclature, 5th ed. Butterworths, London, 1979, 245 pp.
Claxton LD, Stead AG, Walsh D. An analysis by chemical class of Salmonella mutagenicity tests as predictors of animal carcinogenicity. Mutation Res. 1988; 205:197–225.
Commoner B, Vithayathil AU, Dolara P, Nair S, Madyastha P, Cuca GC. Formation of mutagens in beef extract during cooking. Science. 1978;201:913–16.
Fujita Y, Wakabayashi K, Nagao M, Sugimura T. Implication of hydrogen peroxide in the mutagenicity of coffee. Mutation Res. 1985;144:227–30.
Shannon JA, Earle DP Jr, Brodie BB, Taggart JV, Berliner RW. The pharmacological basis for the rational use of atabrine in the treatment of malaria. J Pharmacol Exp Ther. 1944;81:307–30.
Dubin NH, Parmley TH, DiBlasi MC et al. Pharmacology of quinacrine hydrochloride with emphasis on its use as a tubal occluding agent. In: Zatuchni GI, Shelton JD, Goldsmith A, Sciarra JJ, eds. Female Transcervical Sterilization. Philadelphia, Harper and Row, 1983. pp. 60–70.
Laufe LE, Sokal DC, Cole LP, Shoupe D, Schenken RS. Phase I prehysterectomy studies of the transcervical administration of quinacrine pellets. Contraception. 1996;54:181–6.
Patek E. Quinacrine hydrochloride: Review and mode of action of an antimalarial, used as an occlusive agent for transvaginal human sterilization. Acta Obstet Gynecol Scand. 1979;58:561–4.
Gold LS, Bernstein L, Magaw R, Slone TH. Interspecies extrapolation in carcinogenesis: prediction between rats and mice. Environ Health Perspect. 1989;211–19.
Ames BN, Gold LS. Too many rodent carcinogens: mitogenesis increases mutagenesis. Science. 1990;249:970–1.
Godal T. Fighting the parasites of poverty: public research, private industry, and tropical diseases. Science. 1994;264:1864–6.
Kawachi I, Colditz GA, Hankinson S. Long-term benefits and risks of alternative methods of fertility control in the United States. Contraception. 1994;50:1–16.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kessel, E. Quinacrine Sterilization: an Assessment of Risks for Ectopic Pregnancy, Birth Defects and Cancer. Advances in Contraception 14, 81–90 (1998). https://doi.org/10.1023/A:1006556331674
Issue Date:
DOI: https://doi.org/10.1023/A:1006556331674